If you made any changes in Pure these will be visible here soon.

Fingerprint Dive into the research topics where Leslie Samuel is active. These topic labels come from the works of this person. Together they form a unique fingerprint.

  • 36 Similar Profiles
Colorectal Neoplasms Medicine & Life Sciences
Rectal Neoplasms Medicine & Life Sciences
irinotecan Medicine & Life Sciences
Neoplasms Medicine & Life Sciences
oxaliplatin Medicine & Life Sciences
perfluorooctanoic acid Medicine & Life Sciences
Survival Medicine & Life Sciences
Neoadjuvant Therapy Medicine & Life Sciences

Network Recent external collaboration on country level. Dive into details by clicking on the dots.

Research Output 2002 2018

Can Haematology Blood Tests at Time of Diagnosis Predict Response to Neoadjuvant Treatment in Locally Advanced Rectal Cancer?

Ramsay, G., Ritchie, D. T., MacKay, C., Parnaby, C., Murray, G. & Samuel, L., 28 Sep 2018, In : Digestive Surgery. p. 1-7 7 p.

Research output: Contribution to journalArticle

Neoadjuvant Therapy
Hematologic Tests
Hematology
Rectal Neoplasms
Area Under Curve
12 Citations (Scopus)
5 Downloads (Pure)

Inhibition of EGFR, HER2, and HER3 signalling in patients with colorectal cancer wild-type for BRAF, PIK3CA, KRAS, and NRAS (FOCUS4-D): a phase 2–3 randomised trial

Adams, R., Brown, E., Brown, L., Butler, R., Falk, S., Fisher, D., Kaplan, R., Quirke, P., Richman, S., Samuel, L., Seligman, J., Seymour, M., Shui, K. K., Wasan, H., Wilson, R. & Maughan, T., Mar 2018, In : The Lancet Gastroenterology & Hepatology. 3, 3, p. 162–171 9 p.

Research output: Contribution to journalArticle

Open Access
File

Neoadjuvant Anal Cancer VMAT: Lumbrosacral Plexus Dose Volume Histograms with Standard & Escalated Doses proposed in the ACT5 trial.

Findlay, E., Al-Hadjri, T., Wells, L. & Samuel, L., 20 Apr 2018.

Research output: Contribution to conferencePoster

Open Access
Anus Neoplasms
Radiation
Therapeutics
oxaliplatin
Rectal Neoplasms
Radiotherapy
Capecitabine
Margins of Excision
7 Citations (Scopus)
4 Downloads (Pure)

Phase II study of the dual EGFR/HER3 inhibitor duligotuzumab (MEHD7945A) vs. cetuximab in combination with FOLFIRI in RAS wild-type metastatic colorectal cancer

Hill, A. G., Findlay, M., Burge, M., Jackson, C., Garcia Alfonso, P., Samuel, L., Ganju, V., Karthaus, M., Amatu, A., Jeffrey, M., Di Bartolomeo, M., Bridgewater, J., Coveler, A., Hidalgo, M., Kapp, A., Sufan, R., McCall, B., Hanley, W., Penuel, E., Pirzkall, A. & 1 othersTabernero, J., May 2018, In : Clinical Cancer Research. 24, 10, p. 2276-2284 9 p.

Research output: Contribution to journalArticle

Open Access
File
Colorectal Neoplasms
Exons
Exanthema
Diarrhea
Neoplasms